- Home
- DMAC vs CDLX Comparison
DMAC vs CDLX Comparison
Compare DMAC & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CDLX
- Stock Information
- Founded
- DMAC 2000
- CDLX 2008
- Country
- DMAC United States
- CDLX United States
- Employees
- DMAC N/A
- CDLX N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CDLX Computer Software: Programming Data Processing
- Sector
- DMAC Health Care
- CDLX Technology
- Exchange
- DMAC Nasdaq
- CDLX Nasdaq
- Market Cap
- DMAC 190.2M
- CDLX 193.4M
- IPO Year
- DMAC N/A
- CDLX 2018
- Fundamental
- Price
- DMAC $4.36
- CDLX $3.29
- Analyst Decision
- DMAC Strong Buy
- CDLX Hold
- Analyst Count
- DMAC 2
- CDLX 5
- Target Price
- DMAC $7.00
- CDLX $6.38
- AVG Volume (30 Days)
- DMAC 67.1K
- CDLX 699.0K
- Earning Date
- DMAC 11-11-2024
- CDLX 11-06-2024
- Dividend Yield
- DMAC N/A
- CDLX N/A
- EPS Growth
- DMAC N/A
- CDLX N/A
- EPS
- DMAC N/A
- CDLX N/A
- Revenue
- DMAC N/A
- CDLX $305,416,000.00
- Revenue This Year
- DMAC N/A
- CDLX N/A
- Revenue Next Year
- DMAC N/A
- CDLX $7.90
- P/E Ratio
- DMAC N/A
- CDLX N/A
- Revenue Growth
- DMAC N/A
- CDLX 3.10
- 52 Week Low
- DMAC $1.94
- CDLX $2.89
- 52 Week High
- DMAC $4.95
- CDLX $20.52
- Technical
- Relative Strength Index (RSI)
- DMAC 58.96
- CDLX 39.14
- Support Level
- DMAC $4.11
- CDLX $3.01
- Resistance Level
- DMAC $4.48
- CDLX $3.47
- Average True Range (ATR)
- DMAC 0.20
- CDLX 0.21
- MACD
- DMAC -0.00
- CDLX 0.05
- Stochastic Oscillator
- DMAC 74.63
- CDLX 28.28
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.